One film. One randomized trial.
Three-to-one capital leverage.
Project Lucid is the first clinical program testing a sublingual esketamine film for PTSD — a randomized, double-blind, placebo-controlled Phase 1/2a dose-ranging trial with a pre-specified neuroimmune biomarker aim. 505(b)(2) pathway confirmed. LTS Lohmann GMP manufacturing active. Human PK established. A ~$6.25M DoD PRMRP Clinical Trial Award application is in progress to fund the trial itself — so seed capital funds the company, not the trial.
What it is, who it helps, and why it's a two-shots-on-goal asset.
- The drug. 50mg sublingual esketamine film (LTS Lohmann). Bioequivalent Cmax to Spravato 56–84mg intranasal with a metabolite profile favoring synaptogenesis over dissociation.
- The indication + the option. PTSD primary ($3.5B market, no biologic holds the label) + an exploratory neuroimmune biomarker thesis (same cytokines as Skyrizi / Cosentyx / Humira — a $120B shelf).
- The trial. Randomized, double-blind, placebo-controlled Phase 1/2a dose-ranging: N≈84, placebo / 50mg / 100mg, CAPS-5 dose–response primary, pre-specified biomarker aim (CRP, IL-6, TNF-α, BDNF). One trial reads out on efficacy, dose, safety, PK, and mechanism.
- The regulatory path. 505(b)(2) confirmed by FDAMap. Anchors to Spravato's safety package — no new animal tox. At-home delivery unlocked via non-inferiority vs. the Spravato REMS using validated digital monitoring.
- The defensible label. Flexible-dose tiles (25/50/75/100/125/150mg) within one product — a Phase 3 differentiator built on the dose–response question the field has never answered, and this trial does.
- The ask. $3.25M SAFE (post-money cap in the deck). Funds the company — Pre-IND/IND package, patent national-phase filings, placebo film development, operations — while a ~$6.25M DoD PRMRP Clinical Trial Award (application in progress) is positioned to fund the trial. Each seed dollar controls ~3× its value in program spend.
- The exit. Series A at the Phase 1/2a dose–response readout; strategic interest from generic esketamine holders (Teva) and immunology-shelf acquirers on the neuroimmune signal. Otsuka acquired Transcend (methylone, Phase 2 PTSD, n=65) for $700M upfront / up to $1.2B (Mar 2026).
- The team. Richard Idell, MD — Dallas psychiatrist, Sponsor-Investigator. Advisors: Mukesh Kumar (FDAMap, 150+ trials); Steven Idell (40y NIH, Lung Therapeutics acquired); EMMES CRO; The Other Side (patient voice).
The window has never been wider — and the cleanest lane is open.
The post-Lykos landscape has re-prioritized psychiatric assets with clean, placebo-controlled evidence packages. Ketamine's RCT record in PTSD is exactly that. No approved biologic holds the PTSD primary indication. No novel mechanism has been approved in 25 years. And oral ketamine is the first oral NMDA antagonist with transcriptomic evidence of modulating the same cytokines as the immunology shelf's top sellers.
Pre-IND seed SAFE
Series A targeted at the Phase 1/2a dose–response readout. Check size and subscription details on request. Dual funding path: pre-application submitted to the FY26 DoD PRMRP Clinical Trial Award (~$6.25M program; full application September 2026) — peer-reviewed, non-dilutive funding that would carry the trial itself while equity carries the company.
Everything an analyst needs in one place.
Open documents for review. For full access including financial model, protocol redline, IP file, and IND readiness memo, contact investors@lucidptsd.com.
Built by operators with regulatory scars.
Where the $3.25M goes — and what it buys.
The trial itself is designed to be funded by the ~$6.25M DoD PRMRP Clinical Trial Award (application in progress). This round funds everything the grant cannot: the pre-award gap, the costs a federal award doesn't allow, and the working capital that keeps a reimbursement-in-arrears program moving. Allocation is modeled month-by-month against the award timeline.
What this round delivers.
By the readout, the company has produced the assets a Series A investor will underwrite:
- A cleared 505(b)(2) IND, anchored to the Spravato safety package — no new animal tox required.
- A randomized, placebo-controlled CAPS-5 dose–response readout at N≈84 — Phase 2b-ready evidence, not an open-label signal.
- A pre-specified neuroimmune biomarker dataset (CRP, IL-6, TNF-α, BDNF) bridging Wellington 2025 transcriptomics.
- Patent national-phase filings prosecuted — in a 505(b)(2) asset, the IP is most of terminal value.
Five inflection points between seed and Series A.
Each milestone below materially re-rates the asset. Investors entering at the seed SAFE are positioned ahead of all five.
Phase 1 PK complete. 505(b)(2) pathway confirmed by FDAMap. LTS GMP manufacturing active. Protocol v4.2 complete. PCT filed. DoD PRMRP pre-application submitted.
Pre-IND seedFull application to the FY26 Peer Reviewed Medical Research Program Clinical Trial Award (~$6.25M: 12-month planning phase + 4-year trial). CDMRP scientific peer review is itself independent validation.
Non-dilutive leverageWritten-response Pre-IND aligns 505(b)(2) reference products, PK bridging, and CMC. Award notification and anticipated start in late 2027 — trial funding secured without dilution.
Trial funding secured505(b)(2) IND submission and FDA safe-to-proceed, drug and matched placebo supply, site activation, IRB and DoD HRPO approvals. IND clearance materially re-rates the asset.
IND clearanceRandomized CAPS-5 dose–response result at N≈84 with safety, PK, and biomarker data. Phase 2b design, out-licensing conversations, and the Series A follow the readout.
Primary catalystTiming targets reflect the PRMRP award cycle and protocol schedules; actual calendar depends on award timing, FDA review, site activation, and enrollment velocity. If the award is not granted, the trial plan is re-scoped against equity and alternative non-dilutive sources.
What's already proven, what this round proves next, what remains.
The Project Lucid thesis stacks on top of an unusual amount of prior art — an FDA-approved parent product, a validated manufacturing platform, and a confirmed regulatory pathway. The remaining unknowns are small, defined, and directly addressed by this raise.
Before a dollar of this round is spent
- ✓Parent-product safety. Spravato (esketamine) approved 2019; the 505(b)(2) pathway inherits that package — no new animal tox.
- ✓Human PK established. Dahan 2022 characterized the 50mg SL OTF at Cmax ~96 ng/mL (comparable to Spravato 56–84mg).
- ✓GMP manufacturing active. LTS Lohmann thin-film platform in commercial production.
- ✓FDA regulatory pathway confirmed. 505(b)(2) viability signed off by FDAMap (Dr. Mukesh Kumar, 150+ trials).
- ✓Protocol complete. LUCID-PTSD-2026-001 v4.2 — randomized, double-blind, double-dummy, placebo-controlled dose-ranging with independent 3-member DSMB.
- ✓IP position. PCT filed April 2026 after three U.S. provisionals; FTO confirmed.
- ✓CRO engaged. EMMES Corporation engaged for the Phase 1/2a program.
- ✓DoD PRMRP pre-application submitted. FY26 Clinical Trial Award (~$6.25M program); full application September 2026.
What $3.25M + the DoD program produce
- →Cleared 505(b)(2) IND. Written-response Pre-IND, CMC package, IB bridging to Spravato, FDA safe-to-proceed.
- →PTSD efficacy for this formulation. Randomized, placebo-controlled CAPS-5 dose–response at N≈84 — with each active dose tested against placebo.
- →Dose selection for Phase 2b. 50mg vs. 100mg against placebo — the first controlled dose–response data for a regulated sublingual esketamine in PTSD, with a PK substudy including dose proportionality.
- →Pre-specified neuroimmune biomarker readout. CRP and IL-6 as response moderators; TNF-α and BDNF as target engagement — bridging Wellington 2025 transcriptomics.
- →Tolerability at the 3×/week schedule. 12 sessions over 4 weeks matched to the Feder 2021 RCT cadence, with Week-12 durability.
- →Prosecuted IP estate. National-phase entries on the administration and digital monitoring patents — the exclusivity a buyer ultimately pays for.
What a Series A investor underwrites next
- •Award risk. PRMRP is competitive. If not funded, the trial re-scopes against equity and alternative non-dilutive sources — a larger raise, not a dead program.
- •Phase 2b efficacy at scale. Standard pharma risk; mitigated by a randomized dose-ranging Phase 1/2a rather than an open-label pilot.
- •REMS waiver at NDA. At-home label requires FDA signoff on a digital-monitoring concordance package, planned for the Phase 2b program.
- •Commercial scale-out. Telehealth network, reimbursement, prescriber adoption — addressed post-NDA.
- •Competition. No approved PTSD biologic holds the primary indication; no novel mechanism approved in 25 years; post-Lykos no direct at-home competitor.
- •Autoimmune mechanism. Exploratory arm only — not a go/no-go, not bet on for Phase 2 design or Series A valuation.
How the market values assets in this corridor.
The investable space around Project Lucid has both approved-product economics (Spravato) and recent strategic transactions in the psychedelic / NMDA corridor. Project Lucid enters at a pre-IND seed valuation below each of these reference points.
FDA-approved esketamine nasal spray for treatment-resistant depression. Same molecule. In-clinic REMS. Project Lucid targets the same reimbursement tier (~$64K/patient/yr) with an at-home delivery moat and the PTSD primary label.
Methylone (MDMA-analog) PTSD program. Acquired by Otsuka (announced Mar 2026): $700M upfront plus up to $525M in milestones — for a Phase 2 asset with n=65 data (JAMA Psychiatry 2026) and no psychotherapy component. The closest recent strategic comp, and proof big pharma pays up for placebo-controlled PTSD assets.
Scientific advisor Dr. Steven Idell's prior company. Pulmonary-fibrosis franchise developed to Phase 2, acquired into Rein Therapeutics (NASDAQ). Demonstrated path from academic translational science to public-market exit.
Skyrizi (IL-23), Cosentyx (IL-17A), Humira (TNF-α) — the same cytokines modulated by oral ketamine in Wellington 2025 transcriptomics. The pricing corridor is 4× a psychiatric label; Project Lucid is not pricing here, but the mechanism overlap is the exploratory biomarker thesis.
FDA's MDMA rejection (Aug 2024; resubmitted Aug 2026, pending) and the brexpiprazole+sertraline CRL (Sept 2025, 1–10 AdComm vote) reset the bar toward clean placebo-controlled evidence. Ketamine's RCT record (Feder 2021, d=1.13) is that evidence shape — and FDA's April 2026 priority voucher for methylone shows the agency now fast-tracks novel PTSD mechanisms.
Teva (generic esketamine holder), J&J (Spravato franchise), and immunology-shelf acquirers all have strategic overlap. An at-home esketamine label with a placebo-controlled PTSD dataset is a clean bolt-on for each.
Precedents are reference points, not guarantees. Deal economics reflect public reporting and may include earn-outs, milestones, or contingent value. Project Lucid is an investigational candidate; no outcome is assured.
A qualified intake — faster than an email thread.
Share your firm, stage, and check size. Dr. Idell replies within one business day. All submissions are confidential and routed directly to investors@lucidptsd.com.
Let's talk.
Thirty minutes to walk through the thesis, the evidence, and the ask. If we're the wrong fit for your fund, we'd still welcome an intro to someone who is.
This page is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security. Any offering will be made only through definitive documentation. Forward-looking statements regarding clinical and regulatory outcomes are subject to risk. Not medical advice.